SRZN
SRZN
NASDAQ · Biotechnology

Surrozen Inc

$28.96
-1.79 (-5.82%)
As of May 16, 2:06 AM ET ·
Financial Highlights (FY 2026)
Revenue
5.57M
Net Income
-387,578,509
Gross Margin
Profit Margin
-6,960.8%
Rev Growth
-34.7%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 61.1% 61.1%
Operating Margin -1,210.6% -1,089.5% -7.9% -7.5%
Profit Margin -6,960.8% -6,612.7% -5.7% -7.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 5.57M 8.53M 49.01M 58.73M
Gross Profit 29.94M 35.88M
Operating Income -67,410,747 -92,937,610 -3,884,365 -4,377,578
Net Income -387,578,509 -534,345,370 -2,802,997 -4,374,334
Gross Margin 61.1% 61.1%
Operating Margin -1,210.6% -1,089.5% -7.9% -7.5%
Profit Margin -6,960.8% -6,612.7% -5.7% -7.5%
Rev Growth -34.7% -34.7% +7.4% -1.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 78.39M 78.23M
Total Equity 95.79M 82.86M
D/E Ratio 0.82 0.94
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -391,554,275 -569,817,036 -4,562,575 -6,395,991
Free Cash Flow -4,055,082 -5,438,545